Cabaletta Bio Announces Proposed Public Offering of Common Stock
May 17 2023 - 4:01PM
Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA),
a clinical-stage biotechnology company focused on developing and
launching the first curative targeted cell therapies for patients
with autoimmune diseases, announced today that it has
commenced an underwritten public offering of its common stock. All
of the shares are being offered by Cabaletta. In addition,
Cabaletta intends to grant the underwriters a 30-day option to
purchase up to an additional 15% of the number of shares of its
common stock offered in the public offering. The proposed offering
is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
TD Cowen, Evercore ISI and Guggenheim Securities are acting as
joint book-running managers for the proposed offering.
The shares of common stock are being offered by Cabaletta
pursuant a registration statement on Form S-3 that was previously
filed with, and subsequently declared effective on April 26, 2023
by, the Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement and accompanying prospectus relating to and
describing the terms of the offering will be filed with the SEC and
may be obtained, when available, from: Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926,
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, New York 10055; by telephone at
(888) 474-0200, or by email at ecm.prospectus@evercore.com or
Guggenheim Securities, LLC Attention: Equity Syndicate Department,
330 Madison Avenue, New York, NY 10017 by telephone at (212)
518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology
company focused on the discovery and development of engineered T
cell therapies that have the potential to provide a deep and
durable treatment for patients with autoimmune diseases. The CABA™
platform encompasses two strategies: the CARTA (chimeric antigen
receptor T cells for autoimmunity) strategy, with CABA-201, a
4-1BB-containing fully human CD19-CAR T, as the lead product
candidate being evaluated in systemic lupus erythematosus and
myositis, and the CAART (chimeric autoantibody receptor T cells)
strategy, with multiple clinical-stage candidates, including
DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK
myasthenia gravis.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Cabaletta within the meaning of the Private Securities Litigation
Reform Act of 1995, including without limitation, statements
related to the anticipated public offering of shares and the
potential for Cabaletta’s engineered T cell therapies to provide a
deep and durable treatment for patients with autoimmune diseases.
These forward-looking statements include, but are not limited to,
those relating to Cabaletta’s expectations regarding the
completion, timing and size of the public offering and its
expectations with respect to granting the underwriters a 30-day
option to purchase additional shares. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs of future events, and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties related to completion of the proposed public offering
on the anticipated terms, or at all, include, but are not limited
to, market conditions and the satisfaction of customary closing
conditions related to the proposed public offering. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Cabaletta’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Cabaletta’s
most recent annual report on Form 10-K filed on March 16, 2023 and
our subsequent quarterly reports on Form 10-Q and current reports
on Form 8-K filed with the SEC, as well as discussions of potential
risks, uncertainties, and other important factors in Cabaletta’s
other filings with the SEC, including those contained or
incorporated by reference in the preliminary prospectus supplement
related to the proposed public offering to be filed with the
SEC.
Contacts:
Anup MardaChief Financial
Officerinvestors@cabalettabio.com
Sarah McCabeStern Investor Relations,
Inc.212-362-1200sarah.mccabe@sternir.com
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jul 2023 to Jul 2024